Skip to content

Author

Philipp Mandel

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy.

PURPOSE [177Lu]Lu-PSMA-617 is a standard-of-care therapy for metastatic castration-resistant prostate cancer (mCRPC). Given the heterogeneous clinical responses, accessible prognostic tools are needed. We recently demonstrated that the Bellmunt Risk Score (BRS)-comprising ECOG performance status >0, hemoglobin <10 g/dL...

T. Büttner, Mike Wenzel, Philipp Mandel et al. · 0 citations
Open access Sep 2026

Cancer‐Control Outcomes of Japanese Vs. German Metastatic Hormone‐Sensitive Prostate Cancer Patients: A Real‐World Cross‐Country Comparison of Patients Undergoing Combination Therapies

Differences in tumor biology, ethnicities, and healthcare structures across populations may contribute to variability in oncologic outcomes. This study compared baseline characteristics and oncologic outcomes of Japanese and German metastatic hormone‐sensitive prostate cancer (mHSPC) patients.

Mike Wenzel, Keiichiro Miyajima, M. Filzmayer et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.